FDA Approves Subcutaneous Isatuximab: A New Milestone in the Evolution of CD38-Directed Therapy for Multiple Myeloma

Article

July 9, 2026 marked an important advance in the treatment of multiple myeloma as the U.S. Food and Drug Administration approved subcutaneous isatuximab-irfc (Sarclisa Escena®, Sanofi) across all of its established multiple myeloma indications. While the approval does not introduce a new therapeutic target, it represents a meaningful step toward making one of the field's most effective targeted therapies more convenient and accessible for patients. The approval includes subcutaneous isatuximab in combination with: Pomalidomide and dexamethasone for adults who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor. Carfilzomib and dexamethasone for relapsed or refractory multiple myeloma after one to three prior therapies. Bortezomib, lenalidomide, and dexamethasone (VRd) for newly diagnosed patients who are not eligible for autologous stem cell transplantation. The new formulation delivers a fixed 1,400 mg dose by subcutaneous injection using either the CirCLIQ® on-body delivery system or manual administration. Preserving Proven Efficacy The approval was supported by several clinical studies evaluating whether subcutaneous administration could reproduce the efficacy of the established intravenous formulation. The pivotal IRAKLIA Phase 3 trial enrolled more than 500 patients with relapsed multiple myeloma receiving pomalidomide and dexamethasone. Subcutaneous isatuximab achieved an overall response rate (ORR) of 71.1%, essentially identical to the 70.5%observed with intravenous administration while demonstrating appropriate pharmacokinetic exposure. Supporting studies further extended the evidence base: IZALCO demonstrated an ORR of 79.7%when combined with carfilzomib and dexamethasone. IsaSocut reported an ORR of 97.3%among newly diagnosed transplant-ineligible patients receiving isatuximab with VRd. Collectively, these studies demonstrated that patients can receive the same CD38-directed therapy through a more convenient route without compromising clinical activity. Why CD38 Is Such an Effective Target The success of isatuximab begins with the biology of the plasma cell. Plasma cells are among the most specialized cells in the immune system. Their primary responsibility is the continuous production and secretion of antibodies, requiring extraordinary rates of protein synthesis, folding, intracellular transport, and secretion. These demanding processes depend on exquisitely coordinated intracellular calcium signaling. CD38 is far more than a surface marker. It is an ectoenzyme that metabolizes NAD⁺ to produce signaling molecules such ascyclic ADP-ribose (cADPR)andNAADP, which help regulate intracellular calcium release. These calcium signals coordinate many of the activities required for plasma-cell function, including: Protein synthesis Endoplasmic reticulum homeostasis Vesicle trafficking Antibody secretion Cellular activation and survival Because multiple myeloma originates from plasma cells, malignant cells retain exceptionally high CD38 expression and many of the same biological dependencies. Rather than serving simply as an identifying marker, CD38 represents an important signaling hub within one of the body's most metabolically active cell types. How Isatuximab Works Isatuximab exploits this biology by recognizing CD38 on the surface of malignant plasma cells. After binding CD38, it recruits multiple complementary mechanisms that eliminate tumor cells: Antibody-dependent cellular cytotoxicity (ADCC) Antibody-dependent cellular phagocytosis (ADCP) Complement-dependent cytotoxicity Direct induction of apoptosis Reduction of immunosuppressive CD38-positive regulatory immune cells Together, these mechanisms produce deep and durable responses while simultaneously remodeling the bone marrow immune microenvironment. Although CD38 also participates in calcium signaling and NAD⁺ metabolism, current evidence suggests that the antibody's clinical benefit primarily results from immune-mediated elimination of CD38-expressing myeloma cells, with additional contributions from direct tumor-cell effects and immune modulation. Why Drug Delivery Matters At first glance, changing an intravenous infusion into a subcutaneous injection may appear to be a modest innovation. For patients living with multiple myeloma, however, the impact can be substantial. Treatment frequently extends over months or years and often requires repeated visits to infusion centers. Intravenous administration consumes nursing resources, infusion chairs, pharmacy preparation time, and prolonged patient visits. Subcutaneous delivery offers several potential advantages: Shorter treatment visits Reduced infusion-center utilization Greater patient convenience Simplified administration Maintenance of established clinical efficacy As multiple myeloma increasingly becomes a chronic disease, improvements that reduce treatment burden may meaningfully improve quality of life without changing therapeutic effectiveness. The Broader Therapeutic Landscape CD38 antibodies have become one of several foundational pillars of modern multiple myeloma therapy. Immunomodulatory Drugs (IMiDs) Agents such as lenalidomide and pomalidomide stimulate T cells and natural killer cells while directly suppressing myeloma growth, making them ideal partners for CD38-directed antibodies. Proteasome Inhibitors Bortezomib,carfilzomib, andixazomibexploit the extraordinary protein-production demands of plasma cells by disrupting protein degradation, producing endoplasmic reticulum stress and apoptosis. Cereblon E3 Ligase Modulators (CELMoDs) Next-generation agents such as iberdomide and mezigdomide more efficiently degrade the transcription factors Ikaros and Aiolos, enhancing immune responses while directly impairing myeloma-cell survival. BCMA-Directed Therapies Targeting B-cell maturation antigen (BCMA )has transformed the management of advanced disease. This rapidly expanding class includes: Bispecific antibodies Antibody-drug conjugates Autologous CAR T-cell therapies These approaches redirect or engineer the patient's immune system to recognize and destroy malignant plasma cells with remarkable clinical efficacy. Beyond BCMA Researchers are also developing therapies directed against alternative plasma-cell targets including GPRC5D and FcRH5, providing additional options for patients whose disease progresses after BCMA-directed treatment. What's Next? The pace of innovation in multiple myeloma continues to accelerate. While CD38-directed antibodies have become a cornerstone of therapy, the next generation of treatments is focused on overcoming resistance, achieving deeper remissions, and ultimately moving closer to functional cure. One of the most active areas of development is immune cell redirection. New bispecific antibodies engage targets such as BCMA, GPRC5D, or FcRH5 on myeloma cells while simultaneously binding CD3 on T cells, creating highly efficient immune synapses that direct T-cell killing of malignant plasma cells. New molecules with longer dosing intervals and improved safety profiles continue to enter clinical development. CAR T-cell therapy has produced unprecedented response rates in patients with heavily pretreated disease. Current research is moving these therapies earlier in treatment while developing allogeneic "off-the-shelf" products that could expand access and reduce manufacturing delays. Investigators are also targeting the internal biology of plasma cells. Novel therapies are being designed to disrupt protein homeostasis, endoplasmic reticulum stress responses, apoptosis pathways including BCL-2 and MCL-1, metabolic adaptation, DNA repair, and epigenetic regulation. These approaches seek to exploit the unique physiological demands of malignant plasma cells while minimizing toxicity to normal tissues. Equally important is the emergence of precision treatment selection. Advances in measurable residual disease (MRD) testing, genomic profiling, and molecular risk stratification are allowing therapy to become increasingly individualized. Future treatment strategies are likely to consider not only which drug to use, but also the optimal sequence, duration, and timing of therapy for each patient. An Animedix Perspective The approval of subcutaneous isatuximab illustrates an important principle in precision medicine. Innovation is not always about discovering a new molecular target. Sometimes it is about improving how an established therapy reaches patients. CD38 remains one of the most compelling targets in multiple myeloma because it reflects a fundamental biological dependency of plasma cells. The science behind that target has not changed. What has changed is our ability to deliver that therapy more efficiently, reducing the burden of treatment while preserving the clinical benefit demonstrated over years of investigation. As immune engineering, targeted therapeutics, and precision diagnostics continue to evolve, multiple myeloma is being transformed from a disease managed with sequential chemotherapy into one treated through increasingly sophisticated combinations of biologically targeted therapies. The approval of subcutaneous isatuximab is another meaningful step in that evolution—one that demonstrates progress can come not only from discovering new medicines, but also from delivering proven medicines in smarter, more patient-centered ways.